source
- J&J and AbbVie present early trispecific antibody data for multiple myeloma at ASH meetingAt the American Society of Hematology (ASH) meeting, Johnson & Johnson and AbbVie are slated to share early clinical data on trispecific antibodies targeting multiple myeloma. These next‑generation…
- Rezera targets $181 million IPO to fund phase-3 trial of NLRP3 inhibitor for peripheral artery diseaseBoston-based biotech Rezera, which rebranded from NodThera last September, said it will seek an initial public offering to raise about $181 million. The proceeds are intended to move its brain-pene…